Entero Therapeutics Financials
This page shows Entero Therapeutics (ENTO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Entero Therapeutics still runs as a cash-funded development company, with liability reduction reshaping the balance sheet faster than revenue formation.
FY2025 looks cleaner because total liabilities fell by$69.6M and equity swung to$24.9M , but operating cash flow remained negative at-$5.7M and was nearly matched by$5.9M of financing inflow. That combination says the stronger net-worth picture came from a balance-sheet reset rather than the business becoming self-funding.
The income statement is still being driven by a cost base far larger than sales: FY2025 revenue was only
The company is also less liquid than positive equity suggests: cash was just
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Entero Therapeutics's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Entero Therapeutics has an operating margin of -19540.0%, meaning the company retains $-19540 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses.
Entero Therapeutics carries a low D/E ratio of 0.79, meaning only $0.79 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 86/100, indicating a strong balance sheet with room for future borrowing.
Entero Therapeutics's current ratio of 0.17 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Entero Therapeutics generates a -25.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100.
Entero Therapeutics passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Entero Therapeutics generates $0.89 in operating cash flow (-$5.7M OCF vs -$6.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Entero Therapeutics generated $36K in revenue in fiscal year 2025.
Entero Therapeutics's EBITDA was -$6.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 58.2% from the prior year.
Entero Therapeutics reported -$6.4M in net income in fiscal year 2025. This represents an increase of 64.6% from the prior year.
Entero Therapeutics earned $-4.16 per diluted share (EPS) in fiscal year 2025. This represents an increase of 74.0% from the prior year.
Cash & Balance Sheet
Entero Therapeutics held $900K in cash against $0 in long-term debt as of fiscal year 2025.
Entero Therapeutics had 3M shares outstanding in fiscal year 2025. This represents an increase of 112.2% from the prior year.
Margins & Returns
Entero Therapeutics's gross margin was -1813.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs.
Entero Therapeutics's operating margin was -19540.0% in fiscal year 2025, reflecting core business profitability.
Entero Therapeutics's net profit margin was -17634.4% in fiscal year 2025, showing the share of revenue converted to profit.
Entero Therapeutics's ROE was -25.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Capital Allocation
Entero Therapeutics invested $925K in research and development in fiscal year 2025. This represents an increase of 2.4% from the prior year.
ENTO Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $7K-37.2% | $11K-32.8% | $16K | N/A | $207K-5.7% | $220K-60.4% | $555K |
| SG&A Expenses | N/A | $928K+47.7% | $628K-22.0% | $806K | N/A | $1.7M-47.4% | $3.2M-62.5% | $8.5M |
| Operating Income | N/A | -$935K-46.3% | -$639K+22.2% | -$821K | N/A | -$1.9M+44.8% | -$3.4M+62.3% | -$9.1M |
| Interest Expense | N/A | N/A | N/A | $18K | N/A | -$229-5.0% | -$218-100.3% | $66K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | $4.3M+128.6% | -$14.9M |
| Net Income | N/A | -$1.2M-15.5% | -$998K+20.7% | -$1.3M | N/A | -$2.6M+70.7% | -$8.8M-258.2% | $5.6M |
| EPS (Diluted) | N/A | $-0.75-257.1% | $-0.21+25.0% | $-0.28 | N/A | $-1.76+54.4% | $-3.86-1115.8% | $0.38 |
ENTO Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $48.6M-64.1% | $135.4M+59.1% | $85.1M-0.2% | $85.2M-0.2% | $85.4M-0.5% | $85.8M-0.5% | $86.3M-5.3% | $91.1M |
| Current Assets | $2.6M-97.0% | $87.7M+5.3% | $83.3M-0.2% | $83.5M0.0% | $83.5M-0.4% | $83.8M-0.6% | $84.4M+1026.7% | $7.5M |
| Cash & Equivalents | $900K-64.3% | $2.5M+56163.3% | $4K-92.5% | $59K-63.7% | $163K-55.4% | $367K-44.6% | $662K-80.7% | $3.4M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $30K-20.0% | $37K | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | $24.1M-6.5% | $25.8M+1431.7% | $1.7M0.0% | $1.7M0.0% | $1.7M0.0% | $1.7M0.0% | $1.7M-91.6% | $20.0M |
| Total Liabilities | $19.7M-81.7% | $107.5M+17.7% | $91.4M+1.0% | $90.4M+1.3% | $89.3M+15.3% | $77.5M+0.4% | $77.2M+3.0% | $75.0M |
| Current Liabilities | $15.2M-54.8% | $33.5M+12.9% | $29.7M+3.3% | $28.7M+4.3% | $27.5M+75.6% | $15.7M+2.0% | $15.4M+149.2% | $6.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $6.4M |
| Total Equity | $24.9M-10.5% | $27.9M+542.7% | -$6.3M-20.7% | -$5.2M-34.6% | -$3.9M-146.3% | $8.4M-8.2% | $9.1M-43.6% | $16.2M |
| Retained Earnings | -$208.8M-1.4% | -$205.8M-0.6% | -$204.6M-0.5% | -$203.6M-0.6% | -$202.4M-6.4% | -$190.1M-1.4% | -$187.6M-4.9% | -$178.8M |
ENTO Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.0M-364.4% | -$856K-1459.3% | -$55K+93.3% | -$819K-377.3% | -$172K+90.7% | -$1.8M+46.4% | -$3.5M+7.9% | -$3.7M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$13K | N/A | N/A | N/A | $0 | $0 | $0-100.0% | $88K |
| Financing Cash Flow | $2.2M-28.5% | $3.0M | $0-100.0% | $700K+2301.4% | -$32K-102.0% | $1.6M+127.9% | $681K-79.8% | $3.4M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ENTO Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | -4.1% | N/A | N/A | N/A | -30.8%+65.7pp | -96.6%-131.0pp | 34.4% |
| Return on Assets | N/A | -0.9%+0.3pp | -1.2%+0.3pp | -1.5% | N/A | -3.0%+7.2pp | -10.2%-16.3pp | 6.1% |
| Current Ratio | 0.17-2.4 | 2.62-0.2 | 2.81-0.1 | 2.90-0.1 | 3.03-2.3 | 5.34-0.1 | 5.49+4.3 | 1.21 |
| Debt-to-Equity | 0.79-3.1 | 3.86+18.4 | -14.51+2.8 | -17.33+5.7 | -23.03-32.3 | 9.25+0.8 | 8.46+8.1 | 0.40 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: The current ratio is below 1.0 (0.17), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Entero Therapeutics's annual revenue?
Entero Therapeutics (ENTO) reported $36K in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Entero Therapeutics profitable?
No, Entero Therapeutics (ENTO) reported a net income of -$6.4M in fiscal year 2025, with a net profit margin of -17634.4%.
What is Entero Therapeutics's EBITDA?
Entero Therapeutics (ENTO) had EBITDA of -$6.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Entero Therapeutics's gross margin?
Entero Therapeutics (ENTO) had a gross margin of -1813.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Entero Therapeutics's operating margin?
Entero Therapeutics (ENTO) had an operating margin of -19540.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Entero Therapeutics's net profit margin?
Entero Therapeutics (ENTO) had a net profit margin of -17634.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Entero Therapeutics's return on equity (ROE)?
Entero Therapeutics (ENTO) has a return on equity of -25.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Entero Therapeutics's operating cash flow?
Entero Therapeutics (ENTO) generated -$5.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Entero Therapeutics's total assets?
Entero Therapeutics (ENTO) had $48.6M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Entero Therapeutics spend on research and development?
Entero Therapeutics (ENTO) invested $925K in research and development during fiscal year 2025.
What is Entero Therapeutics's current ratio?
Entero Therapeutics (ENTO) had a current ratio of 0.17 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Entero Therapeutics's debt-to-equity ratio?
Entero Therapeutics (ENTO) had a debt-to-equity ratio of 0.79 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Entero Therapeutics's return on assets (ROA)?
Entero Therapeutics (ENTO) had a return on assets of -13.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Entero Therapeutics's cash runway?
Based on fiscal year 2025 data, Entero Therapeutics (ENTO) had $900K in cash against an annual operating cash burn of $5.7M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Entero Therapeutics's Piotroski F-Score?
Entero Therapeutics (ENTO) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Entero Therapeutics's earnings high quality?
Entero Therapeutics (ENTO) has an earnings quality ratio of 0.89x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Entero Therapeutics?
Entero Therapeutics (ENTO) scores 14 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.